This announcement is a separate document:
智飞生物:关于26价肺炎球菌结合疫苗进入Ⅰ/Ⅱ期临床试验的公告
Chongqing Zhifei Biological Products: Announcement regarding the entry of the 26-valent pneumococcal conjugate vaccine into phase I/II clinical trials.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.